trending Market Intelligence /marketintelligence/en/news-insights/trending/YlkHF1fW2lRSZk1pmQZAAQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Moody's says Biogen Alzheimer's trial halt is credit negative

Blog

M&A rebound sparks optimism for near-term deal activity

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud


Moody's says Biogen Alzheimer's trial halt is credit negative

Moody's said Biogen Inc.'s discontinuation of clinical trials for the experimental Alzheimer's drug aducanumab is credit negative for the company.

There is no impact on Biogen's Baa1 senior unsecured rating or the stable rating outlook.

The Cambridge, Mass.-based company, together with Japan's Eisai Co. Ltd., stopped two late-stage clinical trials of the investigational Alzheimer's drug after a futility analysis conducted by an independent data monitoring committee showed that the studies were unlikely to meet their main goals.